VolitionRx Limited develops epigenetics-based diagnostics through its Nucleosomics platform, which measures nucleosomes in blood and other bodily fluids. The company’s Nu.Q® product portfolio spans human diagnostics and monitoring for cancer, sepsis, trauma biomarker research and other disease areas, as well as veterinary oncology through Nu.Q® Vet assays.
VNRX news covers clinical publications and assay-development milestones, commercialization of Nu.Q® tests, veterinary cancer-test development, recombinant nucleosome products under rNuQ™, licensing and distribution activity, financial results, non-dilutive funding, equity financing and NYSE American listing-compliance matters. Volition’s research and development activities are centered in Belgium, with additional operations in the United States and London.
Volition (NYSE AMERICAN: VNRX) reported new clinical and scientific evidence supporting its Nu.Q® NETs platform, focused on the Nu.Q® H3.1 assay as a sepsis biomarker within an estimated $3.8 billion annual total addressable market. Management said it is in active discussions with several large diagnostic companies to accelerate Nu.Q® NETs development.
According to Volition and collaborating clinicians, Nu.Q® H3.1 has shown the ability to distinguish sepsis from non-infectious systemic inflammation, correlate with disease severity, and provide prognostic information on outcomes such as organ failure and mortality. The company highlighted that most supporting papers on its Nu.Q® NETs assay in NETosis-related diseases have now been peer reviewed and published.
Volition (NYSE AMERICAN: VNRX) reported new clinical data on its Nu.Q® Cancer Assay in newly diagnosed non-small cell lung cancer. The study suggests prognostic value for overall and progression-free survival, and may help identify patients suitable for curative care. The paper is under peer review.
Clinical certification at Hospices Civils de Lyon is completed, and a reimbursement dossier is being prepared under France’s RIHN framework. Volition is in discussions with hospital networks and potential licensees and anticipates about €50 revenue per test in a direct sales model.
VolitionRx (NYSE American: VNRX) announced a collaboration with Sysmex (TYO: 6869) to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex diagnostic platform. The partnership supports Volition's strategy to out-license its NETs test globally and target diseases associated with NETosis, including sepsis.
According to Volition, the Nu.Q NETs test aims to aid clinical decision-making, support personalized care, and offer low-cost monitoring of patient condition. The company cites a $3.8 billion Total Addressable Market for the Nu.Q NETs assay.
VolitionRx (NYSE American: VNRX) priced a public offering of 2,960,000 common shares plus warrants for up to 1,480,000 shares at a combined price of $1.55 per share and half warrant, for expected gross proceeds of about $4.6 million before fees.
Warrants are immediately exercisable at $1.55 per share for five years and could add about $2.3 million in gross proceeds if fully exercised. The offering, placed by Maxim Group, is expected to close on June 9, 2026, subject to customary conditions.
Volition (NYSE AMERICAN: VNRX) filed a new patent application to protect use of its Nu.Q® NETs test for triaging and monitoring patients suspected of Ebola infection.
The CE-Marked automated assay and a finger-prick LFT prototype target frontline use in outbreak zones, with Volition actively seeking global strategic partners.
Volition (NYSE AMERICAN: VNRX) reported strong commercial and clinical progress across multi-billion-dollar markets. Q1 2026 revenue reached $1 million, a 300% year-over-year increase, supported by momentum in cancer detection, companion animal health, and sepsis/NETosis applications.
Highlights include a Capture-Seq™ cancer manuscript with >95% sensitivity and 95% specificity in early-stage cancers, a Nu.Q® Vet feline lymphoma study expected to unlock a $5 million milestone upon publication, inclusion of Nu.Q® NETs in the $7.3 million DETECSEPS sepsis program, and progress toward French reimbursement for lung cancer testing. Volition cites annualized TAMs of $23B for Capture-Seq™ cancer detection, $3.8B for Nu.Q® NETs, and $1.0B+ for Nu.Q® Vet canine/feline.
Volition (NYSE AMERICAN: VNRX) reported first quarter 2026 revenue of approximately $1.0 million, up from $0.2 million in 2025, with operating loss down 3%.
Net cash used in operations was $5.3 million. The company raised $5.4 million via its at-the-market facility, $1.9 million from a convertible note and warrant, and received $1 million in non-dilutive Walloon funding, with about $0.9 million more expected over 12 months.
Volition highlighted progress across Nu.Q® Vet (including a feline lymphoma assay manuscript linked to a potential $5 million milestone), Nu.Q® Lung Cancer reimbursement work, and new potential Nu.Q® NETs use cases in acute trauma risk identification and Hidradenitis Suppurativa.
VolitionRx (NYSE AMERICAN: VNRX) will host its first quarter 2026 earnings and business update conference call on Friday, May 15, 2026 at 8:30 a.m. U.S. Eastern Time (2:30 p.m. CET). Senior management will review financial and operating results, key events, and upcoming milestones, with live webcast and replay available.
Volition (NYSE AMERICAN: VNRX) submitted a peer‑review manuscript reporting the Nu.Q® Vet Feline prototype assay detected 86% of feline lymphomas at 97% specificity.
The company says publication is expected to trigger a $5 million contractual milestone and aims to commercialize a blood-based feline cancer screening test via labs and point-of-care channels.
Volition (NYSE AMERICAN: VNRX) announced successful detection of nucleosomes in capillary (finger-prick) blood from ICU sepsis patients using a lateral flow prototype. The study, part of the SUMMIT program, showed feasibility of bedside or home point-of-care testing and referenced prior correlation with venous samples and the automated Nu.Q laboratory assay. Management said the device could enable quantitative, rapid nucleosome readouts and expand access in low-income countries via NGO and strategic partnerships. The company cited an estimated 166 million global sepsis cases as the addressable market.